文献速递淋巴瘤血栓与止血

伊布替尼治疗慢性淋巴细胞白血病的心血管风险:基于人群的队列研究

Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
PubMed 文献 · J Clin Oncol · 2021-08-31

该研究基于加拿大安大略省2007至2019年诊断为CLL的患者数据库,匹配778对伊布替尼治疗与未暴露化疗患者,发现伊布替尼组3年房颤相关医疗接触、出血和心衰风险均显著高于对照组,但缺血性卒中或急性心肌梗死风险无显著差异。

要点

  • 伊布替尼治疗CLL患者3年房颤相关医疗接触发生率为22.7%,对照组为11.7%。
  • 伊布替尼组3年出血风险为8.8%,调整抗凝后出血风险仍升高(HR 2.58)。
  • 伊布替尼组3年心衰风险为7.7%,对照组为3.6%,但卒中或心梗风险无显著差异。

核心结论

  • 伊布替尼与房颤、出血和心衰风险升高相关,但与急性心肌梗死或卒中风险无显著关联。

研究设计与样本

  • 基于人群的队列研究,使用加拿大安大略省关联行政数据库,纳入2007至2019年诊断并治疗的CLL患者。
  • 匹配778对伊布替尼治疗患者与未暴露于伊布替尼的化疗对照,匹配因素包括既往房颤、年龄≥66岁、抗凝暴露和接受伊布替尼的倾向性。

主要发现

  • 伊布替尼组3年房颤相关医疗接触发生率为22.7%(95% CI 19.0-26.6),对照组为11.7%(95% CI 9.0-14.8)。
  • 伊布替尼组3年医院诊断出血风险为8.8%(95% CI 6.5-11.7),对照组为3.1%(95% CI 1.9-4.6)。
  • 调整抗凝作为时变协变量后,伊布替尼仍与出血正相关(HR 2.58;95% CI 1.76-3.78)。
  • 伊布替尼组3年心衰风险为7.7%(95% CI 5.4-10.6),对照组为3.6%(95% CI 2.2-5.4)。
  • 缺血性卒中或急性心肌梗死风险无显著差异。

临床怎么用

  • 接受伊布替尼治疗的CLL患者应加强房颤、出血和心衰的监测与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ibrutinib reduces mortality in chronic lymphocytic leukemia (CLL). It increases the risk of atrial fibrillation (AF) and bleeding and there are concerns about heart failure (HF) and central nervous system ischemic events. The magnitude of these risks remains poorly quantified. METHODS: Using linked administrative databases, we conducted a population-based cohort study of Ontario patients who were treated for CLL diagnosed between 2007 and 2019. We matched ibrutinib-treated patients with controls treated with chemotherapy but unexposed to ibrutinib on prior AF, age ≥ 66 years, anticoagulant exposure, and propensity for receiving ibrutinib. Study outcomes were AF-related health care contact, hospital-diagnosed bleeding, new diagnoses of HF, and hospitalizations for stroke and acute myocardial infarction (AMI). The cumulative incidence function was used to estimate absolute risks. We used cause-specific regression to study the association of ibrutinib with bleeding rates, while adjusting for anticoagulation as a time-varying covariate. RESULTS: We matched 778 pairs of ibrutinib-treated and unexposed patients with CLL (N = 1,556). The 3-year incidence of AF-related health care contact was 22.7% (95% CI, 19.0 to 26.6) in ibrutinib-treated patients and 11.7% (95% CI, 9.0 to 14.8) in controls. The 3-year risk of hospital-diagnosed bleeding was 8.8% (95% CI, 6.5 to 11.7) in ibrutinib-treated patients and 3.1% (95% CI, 1.9 to 4.6) in controls. Ibrutinib-treated patients were more likely to start anticoagulation after the index date. After adjusting for anticoagulation as a time-varying covariate, ibrutinib remained positively associated with bleeding (HR, 2.58; 95% CI, 1.76 to 3.78). The 3-year risk of HF was 7.7% (95% CI, 5.4 to 10.6%) in ibrutinib-treated patients and 3.6% (95% CI, 2.2 to 5.4) in controls. There was no significant difference in the risk of ischemic stroke or AMI. CONCLUSION: Ibrutinib is associated with higher risk of AF, bleeding, and HF, but not AMI or stroke.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Abdel-Qadir H, Sabrie N, Leong D, et al. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. J Clin Oncol. 2021. PMID: 34464154. doi:10.1200/JCO.21.00693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。